Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07819474 | Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With | not yet recruiting | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 |
| clinicaltrials |
| NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.(SIGNAL-IO 301) | not yet recruiting | N/A | 920 | Natera, Inc.INDUSTRY | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07740642 | A Comparative Usability Study of Two Total Body Skin Imaging Systems | not yet recruiting | N/A | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05004792 | Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial(DAHT-RCT) | not yet recruiting | N/A | 258 | Herlev HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07529080 | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial | not yet recruiting | N/A | 142 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07660666 | Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor | not yet recruiting | N/A | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07653087 | Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma(Mel73) | not yet recruiting | N/A | 66 | University of VirginiaOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07307534 | Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study | not yet recruiting | N/A | 60 | Xijing HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07114172 | Study of Melanoma-Resistant PET Monitoring Based on Key Rate-limiting Enzymes for Fatty Acid Metabolism in Healthy Volunteers | not yet recruiting | N/A | 15 | Xijing HospitalOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT07028008 | Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors | not yet recruiting | N/A | 9 | Samsung Medical CenterOTHER | 0 | Jun 26, 2025 | clinicaltrials |
| NCT06553781 | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma | not yet recruiting | N/A | 28 | Fudan UniversityOTHER | 0 | Aug 14, 2024 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials